|
|
Time |
Source |
|
Announcement
|
|
| 17 Mar 2021 |
7:00 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business and Financial Update – FY 2020 |
| 08 Mar 2021 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
OXURION to Participate in Upcoming Investor Meetings |
| 20 Jan 2021 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer |
| 07 Jan 2021 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
OXURION to Participate in Upcoming Investor Meetings |
| 09 Nov 2020 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices |
| 22 Oct 2020 |
5:47 pm |
GNW
|
|
|
Oxurion NV (0G99) |
ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program |
| 15 Oct 2020 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update – Q3 2020 |
| 13 Oct 2020 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer |
| 08 Oct 2020 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET |
| 05 Oct 2020 |
9:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020 |
| 29 Sep 2020 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 |
| 17 Sep 2020 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update - H1 2020 |
| 14 Sep 2020 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference |
| 11 Sep 2020 |
7:15 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September |
| 01 Sep 2020 |
6:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Reports First Patient Dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME) |
| 03 Aug 2020 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer |
| 07 May 2020 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update - Q1 2020 |
| 12 Mar 2020 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update – FY 2019 |
| 09 Feb 2020 |
9:00 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME,at Angiogenesis, Exudation, and Degeneration 2020 Conference |
| 05 Feb 2020 |
6:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference |
| 19 Dec 2019 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME |
| 18 Oct 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update – Q3 2019 |
| 09 Oct 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Provide Business and Clinical Update at Upcoming American Academy of Ophthalmology annual meeting (AAO) and Ophthalmology Innovation Summit (OIS @AAO) in San Francisco |
| 09 Sep 2019 |
4:40 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME |
| 05 Sep 2019 |
4:40 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update – H1 2019 |
| 04 Sep 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME) |
| 02 Sep 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019 |
| 20 Aug 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME |
| 01 Jul 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment |
| 11 Jun 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies |
| 06 Jun 2019 |
6:00 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting |
| 08 May 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV : Oxurion NV Business Update - Q1 2019 |
| 24 Apr 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule |
| 04 Apr 2019 |
6:30 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule |
| 07 Mar 2019 |
4:45 pm |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV Business Update - FY 2018 |
| 28 Feb 2019 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting |
| 04 Feb 2019 |
7:00 am |
GNW
|
|
|
Oxurion NV (0G99) |
Oxurion NV to Present at the 2019 BIO CEO & Investor Conference |
| 19 Oct 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
Oxurion NV Business Update - Q3 2018 |
| 20 Sep 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) |
| |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) |
| 17 Sep 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria |
| 10 Sep 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Websit |
| 06 Sep 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Business Update - H1 2018 |
| 03 Sep 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics becomes "Oxurion" |
| 19 Jul 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) |
| 27 Jun 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Plans Name Change to "Oxurion" |
| 21 Jun 2018 |
7:00 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC |
| 25 May 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) |
| 23 May 2018 |
7:00 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 |
| 09 May 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Business Update - Q1 2018 |
| 06 Apr 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema |
| 04 Apr 2018 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME) |
| 15 Mar 2018 |
4:40 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Business Update - FY 2017 |
| 08 Dec 2017 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate |
| 08 Nov 2017 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer |
| 20 Oct 2017 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics Business Update - Q3 2017 |
| 09 Oct 2017 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR |
| 28 Sep 2017 |
4:35 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US |
| 27 Sep 2017 |
11:05 pm |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting |
| 18 Sep 2017 |
6:30 am |
GNW
|
|
|
ThromboGenics NV (0G99) |
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin) |